Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR8N36)

Drug Name
ML347 Drug Info
Synonyms ML-347
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44577753
TTD Drug ID
DMR8N36

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Activin receptor-like kinase 2 (ALK-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
INCB00928 DMFG8TI Anemia 3A00-3A9Z Phase 2 [2]
TP-0184 DMJVZBC Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PMID27774822-Compound-Figure10Compound12 DMFAGOZ N. A. N. A. Patented [4]
PMID27774822-Compound-Figure10Compound4 DMMJVTW N. A. N. A. Patented [4]
PMID23639540C13d DMSTQGH Discovery agent N.A. Investigative [1]
PMID23639540C13a DMLXOAQ Discovery agent N.A. Investigative [1]
PMID23639540C13r DMHBZ0N Discovery agent N.A. Investigative [1]
LDN-214117 DM57Z8J Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Targeting Activin receptor-like kinase-1 (ACVRL1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-03446962 DMTJWNE Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
PMID23639540C13d DMSTQGH Discovery agent N.A. Investigative [1]
PMID23639540C13a DMLXOAQ Discovery agent N.A. Investigative [1]
PMID23639540C13r DMHBZ0N Discovery agent N.A. Investigative [1]
LDN-214117 DM57Z8J Discovery agent N.A. Investigative [5]
Drug(s) Targeting Bone morphogenetic protein receptor (BMPR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23639540C13d DMSTQGH Discovery agent N.A. Investigative [1]
PMID23639540C13a DMLXOAQ Discovery agent N.A. Investigative [1]
PMID23639540C13r DMHBZ0N Discovery agent N.A. Investigative [1]
LDN-214117 DM57Z8J Discovery agent N.A. Investigative [5]
AA-184 DMCN4ZD Kidney injury NB92.0 Investigative [7]
AA-204 DMBGTX9 Kidney disease GC2Z Investigative [7]
AA-123 DMW73A8 Prostate cancer 2C82.0 Investigative [7]
AA-166 DM2BMAZ Articular cartilage disorder FA34.Y Investigative [7]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activin receptor-like kinase 2 (ALK-2) TTJNBQA ACVR1_HUMAN Inhibitor [1]
Activin receptor-like kinase-1 (ACVRL1) TTGYPTC ACVL1_HUMAN Inhibitor [1]
Bone morphogenetic protein receptor (BMPR2) TTGKF90 BMPR2_HUMAN Inhibitor [1]

References

1 Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
2 Clinical pipeline report, company report or official report of Incyte.
3 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
4 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
5 Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15.
6 ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011 June 30; 117(26): 6999-7006.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).